- The firm also saw other chemotherapy treatment approved by FDA
AstraZeneca revealed that US Food and Drug Administration has approved its lung cancer drug alongside other chemotherapy treatment.
In a statement, Britain’s largest pharmaceutical group said that Imfinzi, in combination with carboplatin and paclitaxel, followed by Imfinzi monotherapy has been approved.
The FTSE 100-listed firm added that this was for for adults suffering with ‘primary advanced or recurrent endometrial cancer that is mismatch repair deficient’ (dMMR).
AstraZeneca revealed that US Food and Drug Administration (FDA) has approved its lung cancer drug alongside other chemotherapy treatment
The approval came after a trial showed that the drug was able reduce ‘the risk of disease progression or death by 58 per cent in patients with dMMR endometrial cancer versus chemotherapy alone.’
Dave Fredrickson, executive vice president, oncology business unit, of AstraZeneca, said: ‘There have been limited advances in the treatment of endometrial cancer in the last few decades, and continued innovation is critical as the burden of this cancer is expected to grow in the future.
‘Immunotherapy in combination with chemotherapy is emerging as a new standard of care in this setting, and the approval of Imfinzi offers an important new option for patients with mismatch repair deficient disease.’
In the US, endometrial cancer is the fourth most common cancer in women, with more than 66,000 patients diagnosed and almost 12,000 deaths in 2022.
The news comes after the Cambridge-based group revealed in April that Imfinzi showed promise in treating highly aggressive small cell lung cancer.
AstraZeneca said the trial demonstrated ‘statistically significant and clinically meaningful improvement’ in survival of patients.
In 2022, just under 2.5 million lung cancer cases were diagnosed globally.
In May, AstraZeneca said it was targeting $80billion in annual revenues by 2030, supported by the launch of 20 new medicines.
Britain’s largest pharmaceutical business achieved $45.8billion in turnover last year, in line with a goal set ten years ago, largely thanks to rising demand for its oncology and diabetes treatments.
It now wants to boost annual turnover by an additional 75 per cent by the start of the next decade through continued growth in sales of its oncology, biopharmaceuticals and rare disease portfolio.
AstraZeneca shares were down 0.26 per cent to 12,478p in Monday morning trading.
***
Read more at DailyMail.co.uk